Acetylcysteine synergizes PD-1 blockers against colorectal cancer progression by promoting TCF1

Animals Colorectal Neoplasms / pathology CD8-Positive T-Lymphocytes / immunology Cell Differentiation / drug effects Programmed Cell Death 1 Receptor / metabolism Mice Acetylcysteine / pharmacology Hepatocyte Nuclear Factor 1-alpha / metabolism Disease Progression Immune Checkpoint Inhibitors / pharmacology Humans Cell Line, Tumor Mice, Inbred C57BL Drug Synergism
Acetylcysteine CD8+ T lymphocytes Colorectal cancer Glucose transporter 4 PD-1 blockade

Journal

Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464

Informations de publication

Date de publication:
17 Oct 2024
Historique:
received: 22 05 2024
accepted: 23 09 2024
medline: 18 10 2024
pubmed: 18 10 2024
entrez: 17 10 2024
Statut: epublish

Résumé

Programmed cell death protein 1 (PD-1) blockade is essential in treating progressive colorectal cancer (CRC). However, some patients with CRC do not respond well to immunotherapy, possibly due to the exhaustion of CD8 We constructed a mouse CRC model to study the effect of NAC on tumors. The effect of NAC on CD8 + T cell differentiation and its potential mechanism were explored using cell flow assay and other studies in vitro and ex vivo. We demonstrated that NAC synergized PD-1 antibodies to inhibit CRC progression in a mouse CRC model mediated by CD8 Our study provides a novel idea for immunotherapy for clinically progressive CRC and suggests that Glut4 may be a new immunometabolic molecular target for regulating CD8

Sections du résumé

BACKGROUND BACKGROUND
Programmed cell death protein 1 (PD-1) blockade is essential in treating progressive colorectal cancer (CRC). However, some patients with CRC do not respond well to immunotherapy, possibly due to the exhaustion of CD8
METHODS METHODS
We constructed a mouse CRC model to study the effect of NAC on tumors. The effect of NAC on CD8 + T cell differentiation and its potential mechanism were explored using cell flow assay and other studies in vitro and ex vivo.
RESULTS RESULTS
We demonstrated that NAC synergized PD-1 antibodies to inhibit CRC progression in a mouse CRC model mediated by CD8
CONCLUSIONS CONCLUSIONS
Our study provides a novel idea for immunotherapy for clinically progressive CRC and suggests that Glut4 may be a new immunometabolic molecular target for regulating CD8

Identifiants

DOI: 10.1186/s12964-024-01848-8 PMID: 39420342
pubmed: 39420342
doi: 10.1186/s12964-024-01848-8
pii: 10.1186/s12964-024-01848-8
doi:

Substances chimiques

Programmed Cell Death 1 Receptor 0
Acetylcysteine WYQ7N0BPYC
Hepatocyte Nuclear Factor 1-alpha 0
Immune Checkpoint Inhibitors 0
Hnf1a protein, mouse 0
Pdcd1 protein, mouse 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

503

Informations de copyright

© 2024. The Author(s).

Références

Wen YF, Chen MX, Yin G, Lin R, Zhong YJ, Dong QQ, et al. The global, regional, and national burden of cancer among adolescents and young adults in 204 countries and territories, 1990–2019: a population-based study. J Hematol Oncol. 2021;14:89. https://doi.org/10.1186/s13045-021-01093-3 .
doi: 10.1186/s13045-021-01093-3 pmcid: 8191013
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660 .
doi: 10.3322/caac.21660
Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134:783–91. https://doi.org/10.1097/CM9.0000000000001474 .
doi: 10.1097/CM9.0000000000001474
Friedlaender A, Naidoo J, Banna GL, Metro G, Forde P, Addeo A. Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC. Cancer Treat Rev. 2022;104:102350. https://doi.org/10.1016/j.ctrv.2022.102350 .
doi: 10.1016/j.ctrv.2022.102350
Marzi L, Mega A, Gitto S, Pelizzaro F, Seeber A, Spizzo G. Impact and novel perspective of immune checkpoint inhibitors in patients with early and intermediate stage HCC. Cancers (Basel). 2022;14. https://doi.org/10.3390/cancers14143332 .
Franco F, Jaccard A, Romero P, Yu YR, Ho PC. Metabolic and epigenetic regulation of T-cell exhaustion. Nat Metab. 2020;2:1001–12. https://doi.org/10.1038/s42255-020-00280-9 .
doi: 10.1038/s42255-020-00280-9
Chen Z, Ji Z, Ngiow SF, Manne S, Cai Z, Huang AC, et al. TCF-1-Centered Transcriptional Network Drives an effector versus exhausted CD8 T cell-fate decision. Immunity. 2019;51:840–e8555. https://doi.org/10.1016/j.immuni.2019.09.013 .
doi: 10.1016/j.immuni.2019.09.013 pmcid: 6943829
Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, et al. Intratumoral Tcf1 + PD-1 + CD8 + T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019;50:195–e21110. https://doi.org/10.1016/j.immuni.2018.12.021 .
doi: 10.1016/j.immuni.2018.12.021 pubmed: 30635237
Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, et al. Defining CD8 + T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537:417–21. https://doi.org/10.1038/nature19330 .
doi: 10.1038/nature19330 pubmed: 27501248 pmcid: 5297183
Utzschneider DT, Charmoy M, Chennupati V, Pousse L, Ferreira DP, Calderon-Copete S, et al. T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity. 2016;45:415–27. https://doi.org/10.1016/j.immuni.2016.07.021 .
doi: 10.1016/j.immuni.2016.07.021
Sen DR, Kaminski J, Barnitz RA, Kurachi M, Gerdemann U, Yates KB, et al. The epigenetic landscape of T cell exhaustion. Science. 2016;354:1165–9. https://doi.org/10.1126/science.aae0491 .
doi: 10.1126/science.aae0491 pmcid: 5497589
Utzschneider DT, Legat A, Fuertes Marraco SA, Carrié L, Luescher I, Speiser DE, et al. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol. 2013;14:603–10. https://doi.org/10.1038/ni.2606 .
doi: 10.1038/ni.2606
Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science. 2016;354:1160–5. https://doi.org/10.1126/science.aaf2807 .
doi: 10.1126/science.aaf2807 pmcid: 5484795
Li X, Wenes M, Romero P, Huang SCC, Fendt SM, Ho PC. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol. 2019;16:425–41. https://doi.org/10.1038/s41571-019-0203-7 .
doi: 10.1038/s41571-019-0203-7
Van Acker HH, Ma S, Scolaro T, Kaech SM, Mazzone M. How metabolism bridles cytotoxic CD8 + T cells through epigenetic modifications. Trends Immunol. 2021;42:401–17. https://doi.org/10.1016/j.it.2021.03.006 .
doi: 10.1016/j.it.2021.03.006 pmcid: 9681987
Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol. 2022;19:37–50. https://doi.org/10.1038/s41571-021-00552-7 .
doi: 10.1038/s41571-021-00552-7
Tsui C, Kretschmer L, Rapelius S, Gabriel SS, Chisanga D, Knöpper K, et al. MYB orchestrates T cell exhaustion and response to checkpoint inhibition. Nature. 2022;609:354–60. https://doi.org/10.1038/s41586-022-05105-1 .
doi: 10.1038/s41586-022-05105-1 pmcid: 9452299
Takata H, Trautmann L. Transforming dysfunctional CD8 + T cells into natural controller-like CD8 + T cells: can TCF-1 be the magic wand? J Clin Invest. 2022;132. https://doi.org/10.1172/JCI160474 .
Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, et al. Subsets of exhausted CD8 + T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20:326–36. https://doi.org/10.1038/s41590-019-0312-6 .
doi: 10.1038/s41590-019-0312-6 pmcid: 6673650
Beltra JC, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z, et al. Developmental relationships of four exhausted CD8 + T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity. 2020;52:825–e8418. https://doi.org/10.1016/j.immuni.2020.04.014 .
doi: 10.1016/j.immuni.2020.04.014 pmcid: 8360766
Brummelman J, Mazza EMC, Alvisi G, Colombo FS, Grilli A, Mikulak J, et al. High-dimensional single cell analysis identifies stem-like cytotoxic CD8 + T cells infiltrating human tumors. J Exp Med. 2018;215:2520–35. https://doi.org/10.1084/jem.20180684 .
doi: 10.1084/jem.20180684 pmcid: 6170179
Adams WC, Chen YH, Kratchmarov R, Yen B, Nish SA, Lin WW, et al. Anabolism-associated mitochondrial stasis driving lymphocyte differentiation over self-renewal. Rep 17 Cell Rep. 2016;17:3142–52. https://doi.org/10.1016/j.celrep.2016.11.065 .
doi: 10.1016/j.celrep.2016.11.065
Alfei F, Zehn D. T cell exhaustion: an epigenetically imprinted phenotypic and functional makeover. Trends Mol Med. 2017;23:769–71. https://doi.org/10.1016/j.molmed.2017.07.006 .
doi: 10.1016/j.molmed.2017.07.006
Gabriel SS, Tsui C, Chisanga D, Weber F, Llano-León M, Gubser PM, et al. Transforming growth factor-β-regulated mTOR activity preserves cellular metabolism to maintain long-term T cell responses in chronic infection. Immunity. 2021;54:1698–e17145. https://doi.org/10.1016/j.immuni.2021.06.007 .
doi: 10.1016/j.immuni.2021.06.007
Pilipow K, Scamardella E, Puccio S, Gautam S, De Paoli F, Mazza EM, et al. Antioxidant metabolism regulates CD8 + T memory stem cell formation and antitumor immunity. JCI Insight. 2018;3. https://doi.org/10.1172/jci.insight.122299 .
Scheffel MJ, Scurti G, Simms P, Garrett-Mayer E, Mehrotra S, Nishimura MI, et al. Efficacy of adoptive T-cell therapy is improved by treatment with the antioxidant N-acetyl cysteine, which limits activation-induced T-cell death. Cancer Res. 2016;76:6006–16. https://doi.org/10.1158/0008-5472.CAN-16-0587 .
doi: 10.1158/0008-5472.CAN-16-0587 pmcid: 5074089
Scheffel MJ, Scurti G, Wyatt MM, Garrett-Mayer E, Paulos CM, Nishimura MI, et al. N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of FoxO1 in an akt-dependent manner. Cancer Immunol Immunother. 2018;67:691–702. https://doi.org/10.1007/s00262-018-2120-5 .
doi: 10.1007/s00262-018-2120-5 pmcid: 5862784
Muniroh M, Gumay AR, Indraswari DA, Bahtiar Y, Hardian H, Bakri S, et al. Activation of MIP-2 and MCP-5 expression in methylmercury-exposed mice and their suppression by N-acetyl-L-cysteine. Neurotox Res. 2020;37:827–34. https://doi.org/10.1007/s12640-020-00174-4 .
doi: 10.1007/s12640-020-00174-4
Xie C, Yi J, Lu J, Nie M, Huang M, Rong J, et al. N-acetylcysteine reduces ROS‐mediated oxidative DNA damage and PI3K/Akt pathway activation induced by Helicobacter pylori infection. Oxid Med Cell Longev. 2018;2018:1874985. https://doi.org/10.1155/2018/1874985 .
doi: 10.1155/2018/1874985 pmcid: 5944265
Ajona D, Ortiz-Espinosa S, Lozano T, Exposito F, Calvo A, Valencia K, et al. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. Nat Cancer. 2020;1:75–85. https://doi.org/10.1038/s43018-019-0007-9 .
doi: 10.1038/s43018-019-0007-9
Tyagi M, Bauri AK, Chattopadhyay S, Patro BS. Thiol antioxidants sensitize malabaricone C induced cancer cell death via reprogramming redox sensitive p53 and NF-κB proteins in vitro and in vivo. Free Radic Biol Med. 2020;148:182–99. https://doi.org/10.1016/j.freeradbiomed.2020.01.011 .
doi: 10.1016/j.freeradbiomed.2020.01.011
Pedre B, Barayeu U, Ezeriņa D, Dick TP. The mechanism of action of N-acetylcysteine (NAC): the emerging role of H2S and sulfane sulfur species. Pharmacol Ther. 2021;228:107916. https://doi.org/10.1016/j.pharmthera.2021.107916 .
doi: 10.1016/j.pharmthera.2021.107916
Jadhav RR, Im SJ, Hu B, Hashimoto M, Li P, Lin JX, et al. Epigenetic signature of PD-1 + TCF1 + CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade. Proc Natl Acad Sci U S A. 2019;116:14113–8. https://doi.org/10.1073/pnas.1903520116 .
doi: 10.1073/pnas.1903520116 pmcid: 6628832
Ma R, Ji T, Zhang H, Dong W, Chen X, Xu P, et al. A Pck1-directed glycogen metabolic program regulates formation and maintenance of memory CD8 + T cells. Nat Cell Biol. 2018;20:21–7. https://doi.org/10.1038/s41556-017-0002-2 .
doi: 10.1038/s41556-017-0002-2
Zhang H, Tang K, Ma J, Zhou L, Liu J, Zeng L, et al. Ketogenesis-generated beta-hydroxybutyrate is an epigenetic regulator of CD8 + T-cell memory development. Nat Cell Biol. 2020;22:18–25. https://doi.org/10.1038/s41556-019-0440-0 .
doi: 10.1038/s41556-019-0440-0
Sena LA, Li S, Jairaman A, Prakriya M, Ezponda T, Hildeman DA, et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity. 2013;38:225–36. https://doi.org/10.1016/j.immuni.2012.10.020 .
doi: 10.1016/j.immuni.2012.10.020 pmcid: 3582741
Siska PJ, Beckermann KE, Mason FM, Andrejeva G, Greenplate AR, Sendor AB, et al. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI Insight. 2017;2. https://doi.org/10.1172/jci.insight.93411 .
Buck MD, O’Sullivan D, Klein Geltink RI, Curtis JD, Chang CH, Sanin DE, et al. Mitochondrial dynamics controls T cell fate through metabolic programming. Cell. 2016;166:63–76. https://doi.org/10.1016/j.cell.2016.05.035 .
doi: 10.1016/j.cell.2016.05.035 pmcid: 4974356
Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity. 2016;45:374–88. https://doi.org/10.1016/j.immuni.2016.07.009 .
doi: 10.1016/j.immuni.2016.07.009 pmcid: 5207350
Vardhana SA, Hwee MA, Berisa M, Wells DK, Yost KE, King B, et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat Immunol. 2020;21:1022–33. https://doi.org/10.1038/s41590-020-0725-2 .
doi: 10.1038/s41590-020-0725-2 pmcid: 7442749
Scharping NE, Rivadeneira DB, Menk AV, Vignali PDA, Ford BR, Rittenhouse NL, et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol. 2021;22:205–15. https://doi.org/10.1038/s41590-020-00834-9 .
doi: 10.1038/s41590-020-00834-9 pmcid: 7971090
Zhu Y, Jing L, Li X, Zheng D, Zhou G, Zhang Y, et al. Decabromodiphenyl ether disturbs hepatic glycolipid metabolism by regulating the PI3K/AKT/GLUT4 and mTOR/PPARgamma/RXRalpha pathway in mice and L02 cells. Sci Total Environ. 2021;763:142936. https://doi.org/10.1016/j.scitotenv.2020.142936 .
doi: 10.1016/j.scitotenv.2020.142936
Qiu J, Villa M, Sanin DE, Buck MD, O’Sullivan D, Ching R, et al. Acetate promotes T cell effector function during glucose restriction. Rep 27 Cell Rep. 2019;27:2063–74. https://doi.org/10.1016/j.celrep.2019.04.022 . .e5.
doi: 10.1016/j.celrep.2019.04.022
Klein Geltink RI, Edwards-Hicks J, Apostolova P, O’Sullivan D, Sanin DE, Patterson AE, et al. Metabolic conditioning of CD8 + effector T cells for adoptive cell therapy. Nat Metab. 2020;2:703–16. https://doi.org/10.1038/s42255-020-0256-z .
doi: 10.1038/s42255-020-0256-z
Gao X, Wang H, Yang JJ, Liu X, Liu ZR. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell. 2012;45:598–609. https://doi.org/10.1016/j.molcel.2012.01.001 .
doi: 10.1016/j.molcel.2012.01.001 pmcid: 3299833
Semenova G, Chernoff J. PKM2 enters the morpheein academy. Mol Cell. 2012;45:583–4. https://doi.org/10.1016/j.molcel.2012.02.014 .
doi: 10.1016/j.molcel.2012.02.014

Auteurs

Wenchang Zhou (W)

Department of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China.
Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China.

Mengdi Qu (M)

Department of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China.
Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China.

Ying Yue (Y)

Department of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China.
Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China.

Ziwen Zhong (Z)

Department of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China.
Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China.

Ke Nan (K)

Department of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China.
Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China.

Xingfeng Sun (X)

Department of Anesthesiology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200438, China.

Qichao Wu (Q)

Department of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China.
Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China.

Jie Zhang (J)

Department of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China.
Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China.

Wankun Chen (W)

Department of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China. chen.wankun@zs-hospital.sh.can.
Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China. chen.wankun@zs-hospital.sh.can.

Changhong Miao (C)

Department of Anesthesiology, Zhongshan Hospital, Cancer Center, Zhongshan Hospital, Fudan University, Fudan University, 180# Feng-Lin Road, Shanghai, 200032, China. miao.changhong@zs-hospital.sh.cn.
Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China. miao.changhong@zs-hospital.sh.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Acetylcysteine synergizes PD-1 blockers...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies du rectum › Tumeurs colorectales › Acetylcysteine synergizes PD-1 blockers...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Acetylcysteine synergizes PD-1 blockers...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Différenciation cellulaire › Acetylcysteine synergizes PD-1 blockers...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Récepteur-1 de mort cellulaire programmée › Acetylcysteine synergizes PD-1 blockers...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Acetylcysteine synergizes PD-1 blockers...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acides aminés soufrés › Cystéine › Acétylcystéine › Acetylcysteine synergizes PD-1 blockers...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs nucléaires hépatocytaires › Facteur nucléaire hépatocytaire HNF-1 › Facteur nucléaire hépatocytaire HNF-1 alpha › Acetylcysteine synergizes PD-1 blockers...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Acetylcysteine synergizes PD-1 blockers...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Inhibiteurs de points de contrôle immunitaires › Acetylcysteine synergizes PD-1 blockers...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Acetylcysteine synergizes PD-1 blockers...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Acetylcysteine synergizes PD-1 blockers...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › Acetylcysteine synergizes PD-1 blockers...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Interactions médicamenteuses › Synergie des médicaments › Acetylcysteine synergizes PD-1 blockers...